BiotechTube
Home/Pipeline/IFx-Hu3.0

IFx-Hu3.0

Not Specified

Not SpecifiedPipeline Asset

Key Facts

Indication
Not Specified
Phase
Not Specified
Status
Pipeline Asset
Company
TuHURA Biosciences

About TuHURA Biosciences

TuHURA Biosciences is a Phase 3 immuno-oncology company with a mission to develop therapeutics that overcome primary and acquired resistance to cancer immunotherapies. Founded in 2019, the company has aggressively built a diversified pipeline through internal R&D and the strategic 2025 acquisition of Kineta, Inc., which added the clinical-stage VISTA inhibitor TBS-2025. TuHURA's strategy focuses on accelerating development via regulatory pathways for unmet needs in both solid tumors (e.g., Merkel cell carcinoma) and hematological cancers (e.g., AML), aiming to broaden the efficacy of existing treatments like checkpoint inhibitors.

View full company profile

Therapeutic Areas

OncologyImmuno-oncology

Other Not Specified Drugs

DrugCompanyPhase
FL116Forlong BiotechnologyNot specified
FL117Forlong BiotechnologyNot specified
FL118Forlong BiotechnologyNot specified
FL301Forlong BiotechnologyNot specified
JSKN016AlphaMab OncologyPhase 1
JSKN033AlphaMab OncologyPhase 1
JSKN022AlphaMab OncologyPhase 1
JSKN027AlphaMab OncologyPhase 1
KN019AlphaMab OncologyPhase 1
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
SR2162SIMR (Australia) BiotechIND Approved